NCT02688101已完成1 期
A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 4
- 主要终点
- Recommended phase 2 dose as determined by number of participants at each dose level with dose limiting toxicities
研究概览
简要总结
Multicenter, open-label, dose-escalation and pharmacokinetic study.
详细描述
Multicenter, open-label, phase 1 study of DpC administered orally to patients with advanced solid tumors. The study will be conducted in two parts. In the first phase successive cohorts of patients (3+3) will receive escalating doses of DpC until the maximum tolerated dose (MTD) is reached. MTD is based on tolerability observed during the first 28 days of treatment. The second part of the study involves treatment of expansion cohorts (10-15 patients each) in specific indications to confirm the tolerability of treatment at the recommended phase 2 dose and schedule and evaluate evidence of anti-tumor activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent prior to initiation of any study-specific procedures;
- •Histologically or cytologically confirmed diagnosis of an advanced or metastatic solid tumor for which standard therapy either does not exist or has proven ineffective, intolerable, or unacceptable for the patient;
- •At least one measurable lesion as defined by RECIST v1.1, except for patients with castrate resistant prostate cancer, who may be enrolled with objective evidence of disease per PCWG2 criteria, and patients with ovarian cancer who may be enrolled without measurable disease but who are evaluable by CA125 per GCIC criteria;
- •life expectancy at least 3 months;
- •ECOG performance status 0-1;
- •Adequate bone marrow reserve, cardiac, renal and liver function, defined by
- •absolute neutrophil count at least 1.5 x 10(9)/L;
- •platelet count at least 100 x 10(9)/L;
- •hemoglobin at least 9 g/dL;
- •ferritin at least 50 ug/L;
- •ECHO shows ejection fraction at least 50% and no evidence of cardiac dysfunction;
- •creatinine clearance >50 mL/min (Cockcroft & Gault formula);
- •AST/ALT no more than 3 x ULN (5 x ULN if liver or bone involvement);
- •serum albumin at least 28 g/L;
- •INR no more than 1.5 x ULN;
- •At least 3 weeks since chemotherapy, immunotherapy, hormone therapy, r other anticancer therapy or surgical intervention or at least 3 half-lie for monoclonal antibodies;
- •Patients with castrate-resistant prostate cancer must maintain ongoing androgen deprivation therapy to provide serum testosterone <50 mg/dL;
- •Patients receiving bisphosphonate or denosumab therapy must be on stable doses for at least 4 weeks before initiating study treatment.
排除标准
- •Inability to swallow oral medications or presence of a GI disorder deemed to jeopardize intestinal absorption of DpC;
- •Persistent grade >1 clinically significant toxicities related to prior anticancer treatment (except alopecia);
- •Known primary CNS malignancy or CNS involvement (except for brain mets that have been treated and are stable and patient is off steroids);
- •History of prior to concomitant malignancies (other than fully excised non-melanoma skin cancer, cured in situ cervical carcinoma, early stage bladder cancer or DCIS of breast) within 3 years of study entry;
- •History of atrial fibrillation or evidence of atrial enlargement on baseline ECHO;
- •History of hemoglobinopathy;
- •Current use of iron chelation therapy;
- •Other serious illness or medial condition;
- •Participation in another clinical trial or treatment with any investigational drug within 30 days prior to study entry;
- •Current use of anticoagulants at therapeutic levels;
- •Pregnant or breast-feeding patients and men and women of child-bearing potential not using effective contraception while on study treatment
研究组 & 干预措施
DpC
Experimental
DpC capsules, administered orally
干预措施: DpC (Drug)
结局指标
主要结局
Recommended phase 2 dose as determined by number of participants at each dose level with dose limiting toxicities
时间窗: 36 months
Determine recommended phase 2 dose
次要结局
- Area under the DpC plasma concentration vs. time curve [AUC] following dosing on Days 1 and 28 based on blood draws taken at 1, 2, 4, 8, and 24 hours after dosing(30 months)
- Number of patients with tumor responses as assessed by RECIST criteria(36 months)
- Maximum DpC plasma concentration [Cmax] following dosing on Days 1 and 28 based on blood draws taken at 1, 2, 4, 8, and 24 hours after dosing(30 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological MalignanciesALLBlast CrisisMDSMultiple MyelomaAMLNCT01204164Tragara Pharmaceuticals, Inc.120
已完成
1 期
Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT01699152Tragara Pharmaceuticals, Inc.16
终止
1 期
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung CancerNSCLC Stage IVNSCLC Stage IIIBAdvanced Non-Small Cell Squamous Lung CancerAdvanced Non-Small Cell Lung CancerAdvanced Non-Small Cell Non-Squamous Lung CancerNon-Small Cell Lung CancerNSCLCNCT05652868Mythic Therapeutics227
已完成
1 期
TrasGEX™: Phase 1 Study in Cancer PatientsSolid TumorsNCT01409343Glycotope GmbH37
已完成
1 期
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) PatientsNon-small Cell Lung CancerNCT00569114Tragara Pharmaceuticals, Inc.45